{"schema_version":"1","generated_at":"2026-11-20T16:48:39.151Z","data_as_of":null,"url":"https://www.findmykol.com/kol/gregory-gerstner","json_url":"https://www.findmykol.com/kol/gregory-gerstner/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"gregory-gerstner","name":"Gregory Gerstner","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Illinois CancerCare","institution_url":"https://www.findmykol.com/institution/illinois-cancercare","city":"Peoria","state":"IL","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"on_file":["npi","orcid","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Gregory Gerstner is an Oncology physician affiliated with Illinois CancerCare. OpenAlex indexes 27 publications with 664 citations (h-index 10).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":27,"cited_by_count":664,"h_index":10,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":26,"program_years":{"first":2021,"last":null},"rows_total":56,"shown":3,"withheld":53,"rows":[{"payer":"Genentech","program_year":2025,"amount_usd":60778.2,"payment_count":24},{"payer":"Bristol Myers Squibb","program_year":2025,"amount_usd":25775,"payment_count":3},{"payer":"Merck & Co.","program_year":2025,"amount_usd":336.63,"payment_count":1}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":13,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":47.1,"classes_total":20,"classes":[{"class":"PD-1 inhibitor","setting":"administered","share_pct":14.2,"drugs":[{"name":"Pembrolizumab","share_pct":85.6},{"name":"Atezolizumab","share_pct":14.4}],"max_beneficiaries":26},{"class":"Microtubule Inhibitor","setting":"administered","share_pct":11.5,"drugs":[{"name":"Paclitaxel","share_pct":83.3},{"name":"Docetaxel","share_pct":16.7}],"max_beneficiaries":28}]},{"area":"Blood & clotting","share_pct":29.1,"classes_total":6,"classes":[{"class":"Iron, parenteral preparations","setting":"administered","share_pct":16.2,"drugs":[{"name":"Ferric carboxymaltose","share_pct":100}],"max_beneficiaries":25},{"class":"Erythropoiesis-stimulating Agent","setting":"administered","share_pct":10.2,"drugs":[{"name":"Darbepoetin alfa","share_pct":100}],"max_beneficiaries":13}]},{"area":"Metabolism & gastrointestinal","share_pct":13.9,"classes_total":6,"classes":[{"class":"Substance P/Neurokinin-1 Receptor Antagonist","setting":"administered","share_pct":6.4,"drugs":[{"name":"Aprepitant","share_pct":100}],"max_beneficiaries":33},{"class":"Other antiemetics","setting":"administered","share_pct":4.5,"drugs":[{"name":"Fosaprepitant","share_pct":100}],"max_beneficiaries":24}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":27,"shown":5,"withheld":22,"matched_by":"OpenAlex author record","recent":[{"title":"The impact of adjusting for c-Kit exon 11 mutation status when comparing prognostic models for gastrointestinal stromal tumors for prediction of recurrence.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e23510","status":"verified"},{"title":"The efficacy of avapritinib for unresectable or metastatic gastrointestinal stromal tumors with and without PDGFRA D842V mutations: A meta-analysis.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.2_suppl.834","status":"verified"},{"title":"Assessing safety and feasibility of virtual reality intervention in patients with lung cancer: a pilot study","year":2025,"journal":"Supportive Care in Cancer","source_url":"https://doi.org/10.1007/s00520-025-09338-4","status":"verified"},{"title":"The risk of venous and arterial thrombosis in polycythemia vera patients with secondary malignancies.","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.e18599","status":"verified"},{"title":"Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study","year":2024,"journal":"Lung Cancer","source_url":"https://doi.org/10.1016/j.lungcan.2024.107924","status":"verified"}],"source":"works"},"similar":[{"name":"Michael Veeder","slug":"michael-veeder","institution":"Illinois CancerCare","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/michael-veeder","json_url":"https://www.findmykol.com/kol/michael-veeder/profile.json"},{"name":"Gary Macvicar","slug":"gary-macvicar","institution":"Illinois CancerCare","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/gary-macvicar","json_url":"https://www.findmykol.com/kol/gary-macvicar/profile.json"},{"name":"Nguyet Le-Lindqwister","slug":"nguyet-le-lindqwister","institution":"Illinois CancerCare","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/nguyet-le-lindqwister","json_url":"https://www.findmykol.com/kol/nguyet-le-lindqwister/profile.json"},{"name":"Francois Geoffroy","slug":"francois-geoffroy","institution":"Illinois CancerCare","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/francois-geoffroy","json_url":"https://www.findmykol.com/kol/francois-geoffroy/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":53,"publications":22}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}